Home / Meet Symeres at DCAT Week 2026
Meet Symeres at DCAT Week 2026
Symeres will be attending DCAT Week 2026 in New York from March 23–26, where leaders from across the pharmaceutical value chain come together to connect, share perspectives, and explore new partnerships.
During DCAT, we look forward to discussing how we can support your programs, whether you are advancing promising discovery assets, addressing complex chemistry challenges, or planning the next stages of development.
If you’re attending DCAT, we would welcome the opportunity to meet and explore how Symeres’ integrated discovery and development capabilities can help move your programs forward efficiently and with reduced risk.
Who may benefit from meeting with Symeres
A conversation may be particularly valuable for:
• Biotech companies advancing promising candidates and seeking integrated discovery, development, or CMC expertise
• Pharmaceutical teams exploring trusted development partners for complex chemistry, drug substance development, or manufacturing support
• Organizations evaluating outsourcing strategies to accelerate timelines while maintaining scientific quality
• Teams working with complex molecules or challenging chemistry that may benefit from specialist expertise
What we can discuss
Symeres partners with biotechnology and pharmaceutical companies across the small-molecule pathway, supporting programs from early discovery through development and into the clinic.
At DCAT, we would be pleased to discuss topics such as:
• Advancing discovery programs through medicinal chemistry expertise
• Addressing complex chemistry challenges in development
• CMC strategy and early development planning
• Drug substance development and manufacturing
• Integrated support from molecule to IND
Attending From Symeres
Guillaume Jetten, Drs., RA
Chief Executive Officer, Symeres
Guillaume Jetten is Chief Executive Officer of Symeres, where he leads the company’s global strategy and growth as a partner to biotechnology and pharmaceutical companies across discovery and development. Since joining Symeres, Guillaume has played a key role in expanding the organization’s international footprint and integrated capabilities across the small-molecule drug development pathway.
With a background in pharmacy and regulatory affairs, Guillaume brings extensive experience in pharmaceutical development, business leadership, and strategic partnerships. He is passionate about enabling scientific innovation and building long-term collaborations that help clients advance their programs efficiently from discovery through development.
Philip Payne
Chief Commercial Officer, Symeres
Philip Payne is Chief Commercial Officer at Symeres, where he leads the company’s global commercial strategy and client partnerships. He works closely with biotechnology and pharmaceutical organizations to align Symeres’ scientific capabilities with the evolving needs of drug discovery and development programs.
Philip brings extensive experience in life sciences outsourcing and business development, with a strong focus on building collaborative relationships that support long-term program success. At Symeres, he plays a key role in connecting partners with integrated discovery, development, and manufacturing solutions.
Michael Mutnansky
Vice President, Business Development, Symeres
Michael Mutnansky is Vice President of Business Development at Symeres, where he focuses on developing strategic partnerships with biotechnology and pharmaceutical companies across North America.
Michael works closely with clients to understand their scientific and development challenges and identify how Symeres’ discovery and development capabilities can support their programs. With experience in life sciences partnerships and a strong understanding of the drug development landscape, he helps organizations navigate outsourcing strategies and accelerate progress toward key development milestones.
